Quick Answer
Lupron (leuprolide) is an androgen-deprivation therapy used in the treatment of prostate cancer. It is not a routine medication for benign prostatic hyperplasia (BPH).
When Lupron is used together with radiation therapy, there is no single treatment duration that applies to every man. Depending on the prostate cancer’s risk group and treatment plan, androgen-deprivation therapy may last only several months or may continue for approximately 18 months to several years.
A very low PSA after treatment can be encouraging, but the PSA result alone does not tell a patient when Lupron should be stopped.
Lupron can also cause important side effects, including hot flashes, sexual problems, fatigue, loss of muscle and bone density, metabolic changes and mood changes. New or worsening depression should be discussed with the treating doctor rather than dismissed as something the patient simply needs to “overcome.”
What Is Lupron?
Lupron Depot is a brand of leuprolide acetate. It belongs to a class of medicines called gonadotropin-releasing hormone, or GnRH, agonists.
Prostate cancer cells often depend on male hormones called androgens, particularly testosterone, for growth. Lupron initially stimulates and then strongly suppresses signaling from the pituitary gland that tells the testes to produce testosterone.
The resulting reduction in testosterone is called androgen-deprivation therapy (ADT).
ADT may be used in several prostate-cancer situations, including in combination with radiation therapy and in men with recurrent, locally advanced or metastatic disease.
Benign prostatic hyperplasia and prostate cancer are different conditions. BPH is generally managed with observation, lifestyle measures, BPH-specific medications or procedures when necessary. You can read about those treatments in my BPH treatment guide .
How Long Is Lupron Given With Radiation?
This is one of the most important questions patients ask, and there is no universal answer such as 12 months or 16 months.
The duration of ADT is determined largely by the patient’s prostate-cancer risk classification and the radiation strategy being used.
| Clinical Situation | Typical Guideline Approach | Important Point |
|---|---|---|
| Favorable intermediate-risk disease | ADT may not be required with radiation in many patients. | Treatment is individualized. |
| Unfavorable intermediate-risk disease | Short-course ADT, commonly about 4–6 months, may be combined with radiation. | The cancer’s risk features matter. |
| High-risk localized disease | Long-term ADT is often combined with radiation. | Guidelines support substantially longer treatment than a few months. |
| Recurrent or metastatic prostate cancer | ADT may be used for a prolonged or ongoing period, often with additional systemic therapy. | This is different from a fixed course given with curative radiation. |
For example, the American Urological Association and American Society for Radiation Oncology recommend short-course ADT of approximately 4–6 months with radiation for unfavorable intermediate-risk prostate cancer.
For high-risk localized prostate cancer, substantially longer ADT is generally used. Current European Association of Urology guidance recommends long-term ADT with radiation, commonly around 2–3 years, depending on the individual clinical situation.
A patient who has received Lupron for one year cannot determine from that number alone whether treatment is complete. The planned stop date should come from the treating radiation oncologist, medical oncologist or urologist who knows the cancer’s stage, grade, risk category and treatment plan.
What About a Gleason Score of 7?
A Gleason score of 7 does not by itself determine how long Lupron should be given.
There is an important difference between Gleason 3+4 and Gleason 4+3, and doctors now also describe these cancers using Grade Groups.
Treatment decisions may also depend on:
- PSA before treatment;
- clinical stage;
- the number and extent of positive biopsy cores;
- whether imaging shows disease outside the prostate;
- whether lymph nodes are involved;
- the radiation treatment used;
- age and general health;
- and other features used to classify the cancer as favorable intermediate, unfavorable intermediate, high risk or another category.
Read more about Gleason score 7 prostate cancer if that page is available on your site.
Does a Very Low PSA Mean Lupron Can Be Stopped?
A very low PSA during or after radiation and ADT is generally encouraging, but it does not automatically mean that treatment should stop.
Lupron suppresses testosterone, and this suppression itself can lower PSA. Therefore, doctors interpret PSA in the context of ongoing hormone therapy, radiation treatment, testosterone levels and the patient’s original cancer risk.
A PSA such as 0.1 ng/mL or lower can be a favorable response, but the planned duration of ADT usually comes from the overall treatment protocol rather than from one PSA measurement.
What Happens After Lupron Is Stopped?
The old version of this page stated that Lupron would necessarily be replaced by other drugs. That is not true for every patient.
Some men receive a defined course of ADT together with radiation and then stop ADT when that planned course is complete. They are subsequently followed with PSA testing and clinical review.
Other men—particularly those with recurrent, advanced or metastatic prostate cancer—may require continued androgen deprivation or additional prostate-cancer medicines.
Whether another medicine is needed depends on the disease situation. There is no automatic rule that every patient must start a replacement medication when Lupron ends.
How Quickly Does Testosterone Recover After Lupron?
Testosterone does not necessarily return to normal immediately after the last injection.
Recovery can take months and varies considerably between men. Age, duration of ADT, baseline testosterone and other health factors can affect how quickly testosterone recovers.
After a longer course of ADT, recovery may be slower, and some older men may have incomplete recovery.
This is one reason PSA after radiation needs to be interpreted alongside the patient’s treatment history and, when clinically useful, testosterone level.
Common Side Effects of Lupron and Androgen-Deprivation Therapy
Lowering testosterone can affect many parts of the body. Some effects appear quickly, while others become more important with prolonged treatment.
Possible effects include:
- hot flashes and sweating;
- reduced sexual desire;
- erectile dysfunction;
- fatigue or reduced energy;
- loss of muscle mass and physical strength;
- increased body fat or weight gain;
- breast tenderness or enlargement in some men;
- loss of bone mineral density and increased fracture risk;
- changes in cholesterol and other blood lipids;
- insulin resistance and increased blood glucose;
- possible worsening or development of diabetes;
- mood changes;
- and depression in some patients.
The National Cancer Institute lists hot flashes, loss of bone density, fractures, loss of muscle and strength, metabolic changes, weight gain, fatigue and mood changes among recognized effects of prostate-cancer hormone therapy.
Can Lupron Cause Depression or Mood Changes?
Yes, mood changes can occur during androgen-deprivation therapy. They should not automatically be blamed only on the cancer itself.
A prostate-cancer diagnosis can understandably create psychological stress, anxiety and depression. At the same time, androgen deprivation may contribute to emotional and quality-of-life changes.
The current Lupron prescribing information specifically reports mood swings, including depression, and advises patients to be counseled about the possibility of developing or worsening depression during treatment.
Therefore, if a family notices that a patient has become persistently withdrawn, hopeless, unusually irritable, severely anxious or markedly different after starting treatment, this deserves discussion with the treating doctor.
Dr. Albana’s Perspective
If a family member tells me that a man receiving Lupron has become very withdrawn or depressed, I would not advise the family simply to tell him to “think positively.”
Cancer itself is emotionally difficult, and androgen-deprivation therapy can also affect mood, energy, sleep, sexuality and physical wellbeing.
I would encourage the family to tell his oncology team specifically what they have noticed: when the changes began, how severe they are, whether he has stopped enjoying normal activities, whether he is sleeping and eating normally, and whether he has expressed hopelessness or thoughts about death.
Depression is a medical condition that can be evaluated and treated. Depending on the situation, support may include counseling, psychiatric or psychological care, medication, exercise and rehabilitation, sleep management, social support or adjustments to other contributing medical problems.
— Dr. Albana Greca, MD, MMedSc
Family Physician / General Practitioner
Suicidal Thoughts Require Urgent Help
If a person receiving cancer treatment says that he wants to die, talks about suicide, has a plan to harm himself, or appears to be in immediate danger, do not treat this as an ordinary treatment side effect and do not leave him alone.
Seek emergency medical or mental-health assistance immediately through the local emergency service or nearest emergency department.
Bone Health During Long-Term ADT
Testosterone helps maintain bone strength. Prolonged androgen deprivation can accelerate loss of bone mineral density and increase fracture risk.
Depending on age, duration of treatment and other risk factors, the treating team may consider:
- assessment of fracture risk;
- a baseline or follow-up bone-density test when appropriate;
- adequate calcium and vitamin D intake;
- weight-bearing and resistance exercise when medically safe;
- stopping smoking;
- limiting excessive alcohol;
- and bone-protective medication in selected high-risk patients.
Supplements should not be started in very high doses without discussing them with the treating clinician.
Blood Sugar, Cholesterol and Cardiovascular Health
GnRH agonists such as Lupron can cause metabolic changes. Current prescribing information warns about hyperglycemia, diabetes, abnormal blood lipids and other features of metabolic syndrome.
Cardiovascular events have also been reported in men receiving GnRH agonists. This does not mean that every patient will develop a heart problem, but it does mean that cardiovascular risk factors deserve attention.
Depending on the individual’s history, monitoring may include:
- blood pressure;
- body weight;
- fasting glucose or HbA1c;
- cholesterol and triglycerides;
- smoking status;
- physical activity;
- and existing heart or vascular disease.
What Is the Initial Testosterone Flare?
Lupron is a GnRH agonist. During the first phase of treatment, it can temporarily increase testosterone before suppressing it.
In men with advanced prostate cancer, this temporary rise can sometimes worsen symptoms such as bone pain or urinary obstruction.
Current Lupron labeling therefore advises careful monitoring during the first weeks, particularly in patients with vertebral metastases or urinary tract obstruction.
The treating oncology team may use additional medication around the start of therapy in selected patients to reduce the clinical consequences of this flare.
Is Lupron the Same as a BPH Drug?
No.
This distinction was blurred in the old version of this page. Lupron is a prostate-cancer hormone therapy, not one of the usual medications used to manage benign prostate enlargement.
Common BPH medication groups include:
- alpha-blockers, which relax smooth muscle around the prostate and bladder neck;
- 5-alpha-reductase inhibitors, such as finasteride and dutasteride, which can gradually reduce prostate volume in appropriately selected men;
- tadalafil in selected patients;
- and combination therapy when clinically appropriate.
For a complete explanation, see: BPH medications: how enlarged-prostate drugs work .
Both contain finasteride, but Proscar is the 5 mg product used for BPH, whereas Propecia is the 1 mg product used for male-pattern hair loss. Patients should use the formulation and dose prescribed for their specific condition.
Questions to Ask Before the Next Lupron Injection
If you are uncertain about how long your treatment should continue, these are useful questions to take to your oncology appointment:
- What is my exact prostate-cancer risk category and stage?
- Was my cancer Gleason 3+4 or Gleason 4+3?
- What Grade Group is my cancer?
- Why was ADT added to my radiation treatment?
- What total duration of ADT was planned when treatment began?
- When is my final Lupron injection expected?
- How are my PSA results being interpreted while my testosterone is suppressed?
- Will you check my testosterone after treatment ends?
- Do I need monitoring of bone density, blood sugar or cholesterol?
- What should I do about hot flashes, fatigue, sexual problems or mood changes?
- Will I need another prostate-cancer medicine after Lupron ends?
Frequently Asked Questions
How long can a man stay on Lupron for prostate cancer?
There is no single maximum duration that applies to everyone. A short course may last several months when combined with radiation for certain intermediate-risk cancers. Higher-risk disease may require considerably longer therapy, while men with recurrent or metastatic cancer may receive ongoing androgen deprivation. The treating oncology team determines the appropriate duration.
Is one year of Lupron enough after radiation?
Possibly for some treatment plans, but not for others. One year cannot be judged as adequate or inadequate without knowing the cancer’s stage, risk classification, Gleason pattern, radiation strategy and intended ADT course. Do not stop treatment based only on the number of months completed.
If my PSA is almost zero, can I stop Lupron?
Not on the basis of PSA alone. Lupron suppresses testosterone and therefore usually suppresses PSA as well. The planned duration of ADT should be followed unless the oncology team changes the treatment plan for a clinical reason.
Can Lupron make someone depressed?
Mood changes and depression have been reported during treatment with Lupron and other forms of androgen-deprivation therapy. Cancer itself can also affect mental health. Persistent or severe mood changes should be reported to the treating clinician.
Does Lupron permanently lower testosterone?
Lupron is intended to suppress testosterone while treatment is active. Testosterone may recover after therapy stops, but recovery can take months and varies substantially between men. Recovery may be slower after prolonged treatment and in older patients.
Does Lupron treat enlarged prostate or BPH?
Lupron is not a routine BPH treatment. Standard BPH treatment uses a different set of medicines and procedures. Although testosterone suppression can affect prostate tissue, the risks and purpose of Lupron make it a prostate-cancer therapy rather than an ordinary enlarged-prostate medicine.
Related Prostate Guides
Medical References
-
American Urological Association and American Society for Radiation Oncology.
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline.
AUA/ASTRO Prostate Cancer Guideline -
European Association of Urology.
EAU Guidelines on Prostate Cancer — Treatment.
EAU Prostate Cancer Guideline -
National Cancer Institute.
Hormone Therapy for Prostate Cancer.
National Cancer Institute -
U.S. National Library of Medicine.
Lupron Depot (leuprolide acetate) Prescribing Information.
DailyMed.
DailyMed: Lupron Depot
Medical information notice: This page provides general patient education and cannot determine how long an individual patient should remain on androgen-deprivation therapy. Prostate cancer treatment depends on stage, Grade Group, PSA, imaging findings, treatment intent, other medical conditions and the treating oncology team’s plan. Do not delay, stop or change Lupron injections without discussing the decision with the clinician responsible for your cancer treatment.
Written & medically reviewed by Dr. Albana Greca, MD, MMedSc • Family Physician / General Practitioner • Last medically reviewed: August 2026